Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 GlobeNewswire - Thu May 21, 4:10PM CDT

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.7000 (+3.03%)
MarketBeat.com
Autolus Therapeutics Q1 Earnings Call Highlights MarketBeat - Thu May 14, 9:07AM CDT

Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates GlobeNewswire - Thu May 14, 6:00AM CDT

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive...

AUTL : 1.7000 (+3.03%)
Can Autolus Therapeutics Prove Its Commercial Therapy Has a Path Beyond Launch Losses? Barchart - Wed May 13, 4:01PM CDT

Barchart Research What to Expect from AUTL Earnings AUTL Generated May 13, 2026 Current Price $1.7100 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 9.27% Can Autolus Therapeutics Prove...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 GlobeNewswire - Tue May 5, 6:00AM CDT

LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction GlobeNewswire - Wed Apr 29, 3:05PM CDT

Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Apr 21, 3:10PM CDT

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Apr 7, 6:00AM CDT

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates  GlobeNewswire - Fri Mar 27, 6:00AM CDT

AUCATZYL ® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL ® UK launch underway following successful...

AUTL : 1.7000 (+3.03%)
Autolus Therapeutics Faces Widening Losses as Analysts Slash Expectations Ahead of Earnings Barchart - Thu Mar 26, 4:01PM CDT

Barchart Research What to Expect from AUTL Earnings AUTL Generated March 26, 2026 Current Price $1.2900 EPS Estimate $-0.31 Consensus Rating Strong Buy Average Move 9.00% Autolus Therapeutics Faces Widening...

AUTL : 1.7000 (+3.03%)

Barchart Exclusives

Can November Soybeans Challenge Contract Highs? Strong Crush Demand and Seasonal Strength Say It's Possible Barchart - Sat May 23, 3:37PM CDT
November soybeans may be setting up one of the better seasonal opportunities in ag markets right now. Record crush demand, bullish technicals, and a weather market season are all lining up at the same time.MRCI research also shows Nov beans closed higher in this seasonal window 12 of the past 15 years, with 8 of those years seeing no daily closing drawdowns.That kind of historical consistency gets traders' attention! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.